Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Dermatology"
DOI: 10.1001/jamadermatol.2022.1185
Abstract: Key Points Question What is the 2-year safety profile of bimekizumab in patients with moderate to severe plaque psoriasis? Findings In this cohort study including 1789 patients receiving bimekizumab, pooled data on 2 years of… read more here.
Keywords: safety; patients moderate; moderate severe; plaque psoriasis ... See more keywords
Ixekizumab: targeting plaque psoriasis and psoriatic arthritis
Sign Up to like & getrecommendations! Published in 2019 at "Prescriber"
DOI: 10.1002/psb.1743
Abstract: Ixekizumab (Taltz) is an anti‐interleukin‐17A monoclonal antibody therapy for the treatment of adults with plaque psoriasis or psoriatic arthritis. This article discusses its efficacy and place in therapy. read more here.
Keywords: psoriatic arthritis; psoriasis psoriatic; ixekizumab; plaque psoriasis ... See more keywords
Tildrakizumab for the treatment of plaque psoriasis in adults
Sign Up to like & getrecommendations! Published in 2019 at "Prescriber"
DOI: 10.1002/psb.1771
Abstract: Tildrakizumab (Ilumetri) is a new biological therapy targeting interleukin (IL)‐23 for the treatment of plaque psoriasis in adults. This article discusses its place in therapy and clinical trial efficacy. read more here.
Keywords: plaque psoriasis; psoriasis adults; treatment plaque;
Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial
Sign Up to like & getrecommendations! Published in 2019 at "Archives of Dermatological Research"
DOI: 10.1007/s00403-019-02024-6
Abstract: Etanercept biosimilar recombinant human tumour necrosis factor-α receptor II: IgG Fc fusion protein (rhTNFR-Fc, trade name Yisaipu) has shown good efficacy in the treatment of moderate-to-severe plaque psoriasis. To compare the efficacy and safety of… read more here.
Keywords: severe plaque; plaque psoriasis; moderate severe; rhtnfr plus ... See more keywords
Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil
Sign Up to like & getrecommendations! Published in 2019 at "Advances in Therapy"
DOI: 10.1007/s12325-019-01049-7
Abstract: Psoriasis is an immune-mediated, chronic, inflammatory disease, which has a substantial humanistic and economic burden. This study aimed to assess the impact of this disease on health-related quality of life (HRQoL), work productivity, and direct… read more here.
Keywords: humanistic economic; severe plaque; psoriasis; plaque psoriasis ... See more keywords
Long-Term Treatment with Dimethyl Fumarate for Plaque Psoriasis in Routine Practice: Good Overall Effectiveness and Positive Effect on Impactful Areas
Sign Up to like & getrecommendations! Published in 2022 at "Dermatology and Therapy"
DOI: 10.1007/s13555-022-00714-0
Abstract: Dimethyl fumarate (DMF) is an oral compound to treat plaque psoriasis. Data on the treatment of patients with psoriasis affecting impactful areas are scarce. In this interim analysis of the prospective, noninterventional SKILL study, we… read more here.
Keywords: plaque psoriasis; treatment; psoriasis; effectiveness ... See more keywords
Patient and Physician Satisfaction with Calcipotriol and Betamethasone Dipropionate Aerosol Foam in the Treatment of Plaque Psoriasis on the Body.
Sign Up to like & getrecommendations! Published in 2019 at "Actas dermo-sifiliograficas"
DOI: 10.1016/j.ad.2019.03.013
Abstract: BACKGROUND AND OBJECTIVE Calcipotriol and betamethasone dipropionate (Cal/BD) aerosol foam is more effective in the treatment of plaque psoriasis than earlier formulations incorporating this combination of active ingredients. The aim of this study was to… read more here.
Keywords: aerosol foam; treatment; plaque psoriasis; aerosol ... See more keywords
Chronic erythema nodosum with koebnerization to plaque psoriasis☆☆☆
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Women's Dermatology"
DOI: 10.1016/j.ijwd.2019.08.009
Abstract: A woman in her 20s with a history of severe plaque psoriasis presented with painful bumps on her lower legs. She had no history of similar lesions. Her medications included cyclosporine, hydroxyzine, and topical steroids… read more here.
Keywords: tender nodules; history; psoriasis; tender ... See more keywords
Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis.
Sign Up to like & getrecommendations! Published in 2019 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2019.05.042
Abstract: Etanercept has greatly improved management considerably. However, the efficacy and safety of combination therapy with methotrexate and the mechanism of action are not known. We aimed to describe the use of combined therapy of etanercept… read more here.
Keywords: combination; severe plaque; group; plaque psoriasis ... See more keywords
Severe pellagra masked by concurrent plaque psoriasis: a case report of a hidden diagnosis.
Sign Up to like & getrecommendations! Published in 2017 at "Dermatology online journal"
DOI: 10.1016/j.jaad.2017.04.909
Abstract: Despite characteristic features, psoriasis can mimic other dermatologic conditions, such as seborrheic dermatitis, lichen simplex chronicus, and certain nutritional deficiencies such as pellagra. We present a patient with a longstanding history of severe plaque psoriasis… read more here.
Keywords: pellagra; diagnosis; psoriasis; plaque psoriasis ... See more keywords
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double‐blinded, placebo‐controlled studies (CIMPASI‐1 and CIMPASI‐2)
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2018.04.012
Abstract: Background Certolizumab pegol, the only Fc‐free, PEGylated anti–tumor necrosis factor biologic, demonstrated clinically meaningful improvements suggestive of a positive risk‐benefit balance in phase 2 studies in adults with moderate‐to‐severe chronic plaque psoriasis. Objective Assess certolizumab… read more here.
Keywords: plaque psoriasis; certolizumab; placebo; treatment ... See more keywords